Journal of Breast Cancer最新文献

{"title":"Solitary Fibrous Tumors of the Breast: Report of Two Cases and Systematic Review.","authors":"Billy Ho Hung Cheung, Sha Zhao, Ava Kwong, Maximus Yeung","doi":"10.4048/jbc.2025.0077","DOIUrl":"https://doi.org/10.4048/jbc.2025.0077","url":null,"abstract":"<p><strong>Purpose: </strong>Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms most commonly found in the pleura, but may also arise in other anatomical locations. Breast SFTs are extremely rare and infrequently reported. Descriptive data on the clinical, radiological, and pathological characteristics of breast SFTs are important for improving understanding of the disease, treatment strategies, and follow-up planning.</p><p><strong>Methods: </strong>The pathology databases of major surgical centers in Hong Kong, covering January 2020 to June 2023, were assessed to identify cases with a diagnostic code for SFT. A systematic literature search was conducted to identify all reported cases of breast SFTs. The search was performed using multiple scientific databases, including PubMed, Web of Science, Embase, and Scopus.</p><p><strong>Results: </strong>We report two cases of breast SFTs in Chinese female patients without a family history of breast cancer. Both patients presented with a palpable breast lump that appeared suspicious on ultrasonography (BI-RADS 4). Both patients underwent surgical excision of the lesions with negative margins. The diagnosis of SFT was established based on immunohistochemical findings in tumor samples obtained from surgical excision. No signs of recurrence were observed at follow-up. A literature review yielded 62 cases of breast SFT, including the two cases reported here. No clinically distinguishing features have been reported in the literature, other than that the majority of patients presented with a mass. SFTs were more commonly found in females (n = 47) than in males (n = 15), although the female-to-male ratio was lower than that observed in other breast cancers.</p><p><strong>Conclusion: </strong>We describe two patients with breast SFTs, together with a comprehensive literature review, to contribute to the currently limited knowledge of this disease. A complete picture of the clinical, radiological, and pathological features of breast SFTs could help improve understanding of the condition and guide appropriate management.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes of Lobular Carcinoma <i>In Situ</i>: Risk of Invasive Cancer Development.","authors":"Doyoun Woen, Ki Jo Kim, Su Min Lee, Seungah Lee, Kawon Oh, Cho Eun Lee, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Woong Ki Park, Hyunwoo Lee, Jonghan Yu","doi":"10.4048/jbc.2025.0272","DOIUrl":"10.4048/jbc.2025.0272","url":null,"abstract":"<p><strong>Purpose: </strong>Lobular carcinoma <i>in situ</i> (LCIS) is a noninvasive lesion associated with an increased risk of invasive cancer. Since its removal from the tumor, node, metastasis classification in the 8th edition of the American Joint Committee on Cancer (AJCC) guidelines, the clinical management of LCIS has shifted from surgery to surveillance. However, studies focusing on the risk and associated factors for invasive cancer development in pure LCIS without ductal carcinoma <i>in situ</i> (DCIS) or invasive cancer remain limited.</p><p><strong>Methods: </strong>We retrospectively analyzed 106 patients diagnosed with pure LCIS between 2008 and 2018. This study evaluated the effect of tamoxifen use and histologic type on the development of invasive cancer.</p><p><strong>Results: </strong>All 106 patients underwent surgery, and nine (8.5%) developed invasive cancer over a median follow-up of 67.5 months. The incidence of invasive cancer was lower in the tamoxifen group (6.3%, n = 4) than in the non-tamoxifen group (11.9%, n = 5), although this difference was not statistically significant (<i>p</i> = 0.266). Pleomorphic LCIS had a significantly higher incidence of invasive cancer (30.0%, n = 3) than classic LCIS (6.3%, n = 6) (<i>p</i> = 0.045). Multivariable Cox regression analysis showed no significant difference in the risk of invasive cancer according to tamoxifen use (hazard ratio [HR], 2.031; 95% confidence interval [CI], 0.544-7.579; <i>p</i> = 0.292). However, pleomorphic LCIS showed a trend toward an increased risk of invasive cancer compared to classic LCIS (HR, 3.856; 95% CI, 0.922-16.126; <i>p</i> = 0.064).</p><p><strong>Conclusion: </strong>Postoperative tamoxifen did not significantly lower invasive cancer development in patients with pure LCIS. Pleomorphic LCIS may carry a higher risk than classic LCIS. These findings require tailored follow-up and treatment strategies based on the histologic subtype of LCIS.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"163-174"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diet and Breast Cancer Survivorship: A Scoping Review.","authors":"Hyun Jeong Cho, Amber Hsiao, Akinkunmi Okekunle, Jung Eun Lee","doi":"10.4048/jbc.2025.0291","DOIUrl":"10.4048/jbc.2025.0291","url":null,"abstract":"<p><p>Survival rates of breast cancer, which is the most common cancer among women, continue to improve. Diet after diagnosis has become an area of interest regarding breast cancer survival, and evidence has accumulated over past decades. Although earlier studies did not offer recommendations beyond general cancer prevention guidelines, more recent findings suggest a potential role of dietary factors in breast cancer prognosis. Healthy dietary patterns have been associated with reduced mortality from non-breast cancer causes. However, associations with breast cancer-specific mortality were less consistent in cohort studies of survivors, most of which were conducted in Western populations. Two randomized intervention trials on the effect of low-fat dietary patterns yielded inconsistent findings, with one study reporting a lower risk of breast cancer recurrence and the other showing no association. Because reduced fat intake is often accompanied by weight loss and increased intake of other dietary components, such as higher vegetable consumption, these factors need to be considered when interpreting the results. Both soy food and dietary fiber intakes have been shown to reduce the risk of all-cause mortality after breast cancer diagnosis. High circulating vitamin D levels may confer benefits, particularly among women with suboptimal vitamin D status. However, the current evidence does not support the protective effect of other individual micronutrients or dietary supplements. Sugar and carbohydrate intake, and coffee consumption remain areas of emerging research interest. In addition, the role of dietary factors should be investigated in specific subgroups, such as premenopausal women, users of antihormone therapy, and those with estrogen receptor-positive or -negative tumors. Importantly, most associations were observed predominantly in Western or postmenopausal populations and may not be generalizable to Asian or younger women. Further studies are needed to clarify the population-specific effects and strengthen the evidence base for dietary recommendations for breast cancer survivors.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"91-117"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Implications of the Langer's Axillary Arch Muscle in Breast Cancer Patients.","authors":"Eunhye Kang, Ji-Jung Jung, Hong-Kyu Kim, Han-Byoel Lee, Wonshik Han, Jung Min Chang, Hyeong-Gon Moon","doi":"10.4048/jbc.2025.0264","DOIUrl":"10.4048/jbc.2025.0264","url":null,"abstract":"<p><strong>Purpose: </strong>Langer's axillary arch (LAA) is a common muscular variant that may affect the assessment of axillary lymph nodes in breast cancer. We investigated whether the presence of the LAA had a meaningful clinical impact in a large cohort of Korean patients with breast cancer.</p><p><strong>Methods: </strong>The medical records and imaging of 2,904 patients (2,953 cases) who underwent axillary surgery for breast cancer were reviewed. The presence of LAA was determined using chest computed tomography scans. The number of retrieved lymph nodes, the accuracy of axillary ultrasonography, and survival outcomes were compared between the LAA and non-LAA groups.</p><p><strong>Results: </strong>The LAA muscle was identified in 301 patients (10.2%). Preoperative ultrasound evaluation showed a lower specificity in the LAA group (77.9% vs. 83.6%, <i>p</i> = 0.031). Additionally, invasive disease-free survival (iDFS) was significantly worse in the 'LAA-positive patients' after adjusting for stage, histologic grade, and treatment (adjusted hazard ratio, 2.00; 95% confidence interval, 1.00-4.01; <i>p</i> = 0.048), with regional axillary recurrence being notably more frequent in patients with the LAA muscle (<i>p</i> = 0.005).</p><p><strong>Conclusion: </strong>The presence of the LAA muscle was associated with reduced specificity on preoperative ultrasound. Patients with LAA muscle-associated tumors had worse iDFS, with regional axillary recurrence occurring more frequently. Recognition of the LAA muscle during axillary staging and surgery may improve nodal assessment accuracy and outcomes, especially in the era of axillary surgery de-escalation.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"29 2","pages":"154-162"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147815736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sentinel Lymph Node Analysis in Patients With Breast Cancer Revealed Alterations in T Cells Subset.","authors":"Maria Eduarda Cunha-Silva, Laura Otto Walter, Daniella Serafin Couto Vieira, Yasmin Camile de Souza, Lisandra de Oliveira Silva, João Vitor Steimbach, Maria Cláudia Santos-Silva","doi":"10.4048/jbc.2026.0014","DOIUrl":"10.4048/jbc.2026.0014","url":null,"abstract":"<p><p>In breast cancer, sentinel lymph nodes (SLNs) represent the first site of interaction between tumor-derived antigens and the host immune system. However, descriptive data on immune cell subsets within the SLN remains limited. This exploratory study evaluated immune cell populations in SLN samples from women with invasive breast cancer (IBC) using flow cytometry, and assessed their distribution according to clinicopathological characteristics. SNL scrapings were collected from 22 patients with IBC. SNL cells were evaluated using flow cytometry, and the results were compared with clinical and pathological variables, such as tumor subtype, axillary status, lymphovascular invasion (LVI), histological grades, and expression of estrogen receptors (ERs) and human epidermal growth factor receptor 2 (HER2). The frequencies of monocytes and neutrophils were not significantly correlated with the clinical variables analyzed. In patients with LVI, there was an increase in the frequency of CD4⁺ T cells and programmed death-1 (PD-1) expression in CD8⁺ T-cells. Furthermore, a reduction in central memory CD4⁺ T cells and an increase in terminal effector memory CD4⁺ T cells were observed in patients with histological grade III disease compared to those with histological grade I disease. It was also observed that in patients expressing ERs and HER2, there was an increase in PD-1 and programmed death-ligand 1 expression in CD8⁺ T-cells. These findings provide a descriptive overview of immune cell distribution in SLNs according to their clinicopathological features. These results are preliminary and hypothesis-generating, supporting the need for larger longitudinal studies to further characterize the immune profiles within tumor-draining lymph nodes.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"175-182"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in identifying sentinel lymph nodes in early breast cancer patients: Should we opt for standard axillary lymph node dissection?","authors":"Jun Hyung Bang, Seokwon Lee","doi":"10.4048/jbc.2025.0193","DOIUrl":"https://doi.org/10.4048/jbc.2025.0193","url":null,"abstract":"<p><strong>Purpose: </strong>Assessing the metastatic status of axillary lymph nodes is critical in breast cancer to determine disease progression and guide treatment. Axillary lymph node dissection (ALND) is performed when sentinel lymph nodes (SLN) are undetectable; however, this can lead to overtreatment and complications. This study investigated whether limited ALND provides outcomes comparable to those of standard ALND in patients with early stage breast cancer.</p><p><strong>Methods: </strong>Medical records of 2,461 patients were reviewed, focusing on 304 cases with undetectable SLNs. After excluding those with three or more metastatic nodes, 217 patients with early-stage disease were analyzed. They were classified into limited ALND (L-ALND; ≤9 nodes removed) and standard ALND (S-ALND; ≥10 nodes removed) groups.</p><p><strong>Results: </strong>The L-ALND group had a lower local recurrence rate (1.6% vs. 3.4%) and fewer complications than the S-ALND group. Similarly, the five- and ten-year recurrence-free survival rates were higher in the L-ALND group than in the S-ALND group (95.0% vs 89.1% and 94.2% vs 49.5%). Factors affecting recurrence included the ALND type (S-ALND vs. L-ALND), type of operation, and tumor subtype. The incidence of lymphedema was also lower in the L-ALND group than in the S-ALND group (4.8% vs. 10.3%).</p><p><strong>Conclusions: </strong>Limited ALND offers outcomes comparable to standard ALND in early-stage breast cancer, reducing complications without compromising oncological outcomes.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline Mutations Related to Complete Remission After Neoadjuvant Chemotherapy in Patients With Triple-negative Breast Cancer.","authors":"Jee Hyun Ahn, Ji Soo Park, Dongju Won, Seung-Tae Lee, Suk Jun Lee, Seung Hye Yang, Jee Ye Kim, Seho Park, Seung Il Kim, Byeong-Woo Park, Min Hwan Kim, Gun Min Kim, Joohyuk Sohn, Hyung Seok Park","doi":"10.4048/jbc.2025.0172","DOIUrl":"10.4048/jbc.2025.0172","url":null,"abstract":"<p><strong>Purpose: </strong>Triple-negative breast cancer (TNBC) is a frequent phenotype of <i>BRCA</i>-mutant tumors. Tumors with BRCAness may show characteristics of <i>BRCA</i>-mutant tumors and respond to similar treatments. Next-generation sequencing is an efficient and cost-effective method for simultaneously sequencing multiple cancer susceptibility genes, surpassing conventional Sanger testing.</p><p><strong>Methods: </strong>A total of 148 women with TNBC were recruited from December 2015 to November 2018, as part of a sub-analysis based on the PEARLY trial data. Of them, 103 patients received neoadjuvant chemotherapy (NCT). The targeted genes related to hereditary cancers were sequenced using the 65-gene germline next-generation sequencing (gNGS) panel pathogenic and likely pathogenic variants (P&LPs) were determined by Sanger sequencing. We examined the occurrence of pathologic complete remission (ypCR) in patients with P&LPs.</p><p><strong>Results: </strong>The patients' median age was 47 years (range, 27-69 years). Twenty (13.7%) of 148 patients had P&LP in six genes, including <i>BARD1</i> (n = 2), <i>BRCA1</i> (n = 9), <i>BRCA2</i> (n = 5), <i>CHEK2</i> (n = 1), <i>RAD51C</i> (n = 1), and <i>RAD51D</i> (n = 2). Among the 103 patients with NCT, 43 (41.7%) achieved ypCR (P&LPs; 9 individuals vs. non-variants; 34 individuals). Among the 103 patients with NCT, 14 (9.3%) had P&LPs. Nine of 14 patients with P&LPs, including <i>BARD1</i> (n = 2), <i>BRCA1</i> (n = 4), <i>BRCA2</i> (n = 1), <i>RAD51C</i> (n = 1), and <i>RAD51D</i> (n = 1), achieved ypCR, showing a trend toward statistical significance (<i>p</i> = 0.066).</p><p><strong>Conclusion: </strong>Germline P&LP mutations in TNBC patients can be detected by gNGS. This panel test can identify <i>BRCA</i> and BRCAness mutations that may predict ypCR in TNBC.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"118-127"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-Based Exosome Analysis for Improving Diagnostic Performance of Breast Lesions on Ultrasound: Protocol of a Prospective, Multicenter Cohort Study.","authors":"Sung Eun Song, Hyunku Shin, Yong Park, Yeonho Choi, Seung Pil Jung","doi":"10.4048/jbc.2025.0206","DOIUrl":"10.4048/jbc.2025.0206","url":null,"abstract":"<p><strong>Purpose: </strong>Exosome-surface enhanced Raman spectroscopy-artificial intelligence platform (exosome-SERS-AI) is an innovative liquid biopsy method that acquires SERS signals from plasma exosomes and analyzes them using deep learning models to diagnose cancer. This study aimed to evaluate whether exosome-SERS-AI could increase the diagnostic accuracy of ultrasonography (US) for suspicious breast lesions.</p><p><strong>Methods: </strong>This prospective multicenter study enrolled 500 patients between November 2024 and December 2025. Eligible participants will be women aged ≥ 40 years who will undergo US performed by specialized breast radiologists and have suspicious breast lesions assigned to a Breast Imaging Reporting and Data System (BI-RADS) category 3-5 assessment. A 6 mL whole blood sample was collected from each participant. After plasma separation, SERS, which is highly sensitive to exosomes, was employed to measure Raman signals, and the acquired data were processed using artificial intelligence algorithms. Following sampling, all patients underwent US-guided core needle biopsy for breast lesions classified as BI-RADS category 4 and 5, and 12-months of follow-up US for lesions classified as BI-RADS category 3. Histopathological examination was used as the reference standard for BI-RADS 4 and 5 lesions, whereas stability on 12-month follow-up US was used as the reference standard for BI-RADS 3 lesions. The cohort is expected to have an equal distribution of benign and malignant cases. The following outcome measures were compared between US alone and the combination of exosome-SERS-AI with US: sensitivity, specificity, positive predictive value, negative predictive value, and the area under the receiver operating characteristic curve. Enrollment is expected to be completed by 2025, and the study results are expected to be presented in 2026.</p><p><strong>Discussion: </strong>This prospective multicenter study will evaluate the performance of exosome-SERS-AI compared to US in women with BI-RADS categories 3-5. Participant enrollment is ongoing.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT06672302. Registered on November 4, 2024.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"183-191"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Real-World Efficacy and Safety of KEYNOTE-522 Regimen in Patients With Early Triple-Negative Breast Cancer.","authors":"Shinyoung Lee, Hyehyun Jeong, Yeokyeong Shin, Jae Ho Jeong, Kyung Hae Jung, Sung-Bae Kim, Byung-Kwan Jeong, Hee Jin Lee, Gyungyub Gong, Hee Jung Shin, Hye Joung Eom, Young-Jin Lee, Tae-Kyung Yoo, Sae Byul Lee, Jisun Kim, Il-Yong Chung, Beom-Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Jin-Hee Ahn","doi":"10.4048/jbc.2025.0256","DOIUrl":"10.4048/jbc.2025.0256","url":null,"abstract":"<p><strong>Purpose: </strong>Based on the KEYNOTE-522 study, neoadjuvant pembrolizumab plus chemotherapy has become the standard treatment for early-stage triple-negative breast cancer (TNBC). This study evaluated the real-world efficacy, safety, and predictors of pathologic complete response (pCR) in Korean patients.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 174 patients with early-stage TNBC who received the KEYNOTE-522 regimen (neoadjuvant pembrolizumab plus paclitaxel and carboplatin, followed by doxorubicin and cyclophosphamide) at a tertiary cancer center between August 2022 and July 2024. We assessed the primary endpoints, including pCR rate and event-free survival (EFS). We performed univariable and multivariable logistic regression analyses to identify independent predictors of pCR.</p><p><strong>Results: </strong>The median patient age was 50 years (range, 24-74 years). The clinical stages were II and III in 79.3% and 20.1% of patients, respectively, and 10.9% had clinical N3 disease. The overall pCR rate was 62.1%, and the N3 subgroup had a pCR rate of 47.4%. On multivariable analysis, high baseline Ki-67 expression (≥ median, 75%) was significantly associated with pCR (odds ratio, 2.84; 95% confidence interval, 1.45 to 5.66; <i>p</i> = 0.002). At a median follow-up of 18.4 months, the 12-month EFS rate was 97.4%, with significantly superior outcomes observed in patients who achieved pCR compared with those who did not achieve pCR (100% vs. 93.1%, <i>p</i> = 0.007). The treatment completion rate was 92.0%, and immune-related adverse events occurred in 13.8% of patients.</p><p><strong>Conclusion: </strong>In this real-world analysis of one of the largest Asian cohorts of patients with early-stage TNBC treated with neoadjuvant pembrolizumab, the KEYNOTE-522 regimen demonstrated substantial efficacy and manageable toxicity, consistent with the original trial findings.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"141-153"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed Bleeding With Variable Presentations in Implant-Based Breast Reconstruction During Adjuvant Ado-Trastuzumab Emtansine (Kadcyla) Therapy: Two Case Reports.","authors":"Seong Jun Ryu, Young Seok Kim, In Sik Yun, Kyunghyun Min, Joon Jeong, Tai Suk Roh","doi":"10.4048/jbc.2025.0278","DOIUrl":"10.4048/jbc.2025.0278","url":null,"abstract":"<p><p>Ado-trastuzumab emtansine (T-DM1) is an effective adjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer; however, its surgical safety profile remains unclear. We observed delayed bleeding with variable and often subtle clinical manifestations during implant-based breast reconstruction (IBBR). Two patients who received adjuvant T-DM1 therapy after IBBR were retrospectively reviewed. The patient in Case 1 developed a recurrent seroma and liquefied hematoma requiring repeated aspirations, with platelet counts decreasing from 218 × 10⁹/L to 33 × 10⁹/L before expander removal. The patient in Case 2 experienced an acute massive hematoma on postoperative day (POD) 2, prior to T-DM1 initiation, which resolved after re-exploration; a temporally distinct delayed hemorrhagic event occurred on POD 175 during T-DM1 therapy after radiotherapy, accompanied by a platelet nadir of 34 × 10⁹/L. Both patients required plateletpheresis and prolonged drainage. Delayed bleeding during T-DM1 therapy may reflect a combination of hematological suppression and vascular vulnerability. Therefore, vigilant surveillance and cautious postoperative rehabilitation are warranted.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"29 2","pages":"192-201"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}